EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kronos Bio's enterprise value is $-85.83 Mil.
Kronos Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-119.69 Mil. Therefore, Kronos Bio's EV-to-EBITDA for today is 0.72.
The historical rank and industry rank for Kronos Bio's EV-to-EBITDA or its related term are showing as below:
KRON'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.51 Med: 0.72 Max: 0.95
Current: 0.72
During the past 6 years, the highest EV-to-EBITDA of Kronos Bio was 0.95. The lowest was 0.51. And the median was 0.72.
KRON's EV-to-EBITDA is ranked better than 72.77% of 470
companies
in the Biotechnology industry
Industry Median: 9.14
vs KRON: 0.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-26), Kronos Bio's stock price is $1.00.
Kronos Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.950. Therefore, Kronos Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Kronos Bio EV-to-EBITDA Historical Data
The historical data trend for Kronos Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kronos Bio's EV-to-EBITDA
For the Biotechnology subindustry, Kronos Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kronos Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kronos Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kronos Bio's EV-to-EBITDA falls into.
Kronos Bio EV-to-EBITDA Calculation
Kronos Bio's EV-to-EBITDA for today is calculated as:
Kronos Bio's current Enterprise Value is $-85.83 Mil.
Kronos Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kronos Bio (NAS:KRON) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kronos Bio's share price for today is $1.00.
Kronos Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Kronos Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRON has been successfully added to your 